The Capital District practice is one of the first organizations in the area to introduce the FDA-approved treatment that eliminates moderate to severe fat below the chin, also known as the “double chin.”
Albany, N.Y., July 6, 2015 – The Plastic Surgery Group, the leading Capital District plastic surgery practice, announced today the availability of KYBELLA™. KYBELLA is the first and only FDA approved injectable that treats the fat beneath your chin and causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat which results in a smoother, leaner appearance of the chin and neck.
Excess fat on the chin, also known as submental fullness, is often referred to as a “double chin,” and it is a common facial aesthetic condition. It can impact a broad range of adults, including both men and women, and can be influenced by several factors such as aging, genetics and weight gain. In the past, the condition was commonly undertreated due to lack of reliable treatments along with resistance to diet and exercise.
According to a 2014 survey conducted by the American Society for Dermatologic Surgery (ASDS), 68% of people said they’re bothered by under-the-chin fullness and are just as bothered by their double chins as they are by the lines and wrinkles around and under their eyes. In clinical studies, KYBELLA has shown that 79% of patients treated with Kybella reported satisfaction with the appearance of their face and chin.
KYBELLA has only been made available to a select group of trained physicians throughout the country and Dr. Jeffrey Rockmore, a board certified cosmetic surgeon at The Plastic Surgery Group, is one of the doctors who has been selected and certified to administer KYBELLA to patients. Dr. Rockmore said “I’m very excited to have the opportunity to have this ground-breaking injectable available to my patients. The non-surgical and safe procedure is performed right in our Albany office and patients will see improvement in just two to four treatment sessions spaced about a month apart.”
KYBELLA has been one of the most buzzed about injectables since its FDA approval in April. In fact, this past June, Allergan announced that it will be seeking to purchase Kythera, the maker of KYBELLA, for $2.1 billion adding to its portfolio of high profile aesthetic drugs like Botox, Juvederm, and Latisse.
For more information about The Plastic Surgery Group or to schedule an appointment for KYBELLA, visit ThePlasticSurgeryGroup.net or call 518.438.0505. Additional information can be found on Facebook or Twitter.